Solventum (SOLV)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
$76.28-2.13%
Close 2026-07-07 · 1-day change
Reading SOLV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SOLV free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
Reading SOLV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track SOLV free→QuarterlyIQ Insights · SOLV
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenues | 8,262.0 | 8,325.0 | 8,254.0 | 8,197.0 | 8,130.0 | — |
| Total Revenues | 8,262.0 | 8,325.0 | 8,254.0 | 8,197.0 | 8,130.0 | — |
| Gross Profit | 4,434.0 | 4,451.0 | 4,593.0 | 4,693.0 | 4,695.0 | — |
| Operating Expenses & Income | ||||||
| Selling, General & Admin | 3,138.0 | 3,080.0 | 2,782.0 | 2,299.0 | 2,235.0 | — |
| R&D Expenses | 735.0 | 739.0 | 775.0 | 758.0 | 767.0 | — |
| Operating Income | — | 2,181.0 | 1,036.0 | 1,692.0 | 1,693.0 | — |
| Earnings from Continuing Operations | ||||||
| EBT, Incl. Unusual Items | 1,691.0 | 1,713.0 | 605.0 | 1,667.0 | 1,692.0 | — |
| Income Tax Expense | 259.0 | 157.0 | 127.0 | 321.0 | 349.0 | — |
| Net Income | ||||||
| Net Income | 1,432.0 | 1,556.0 | 479.0 | 1,346.0 | 1,343.0 | — |
| Per Share | ||||||
| Basic EPS | 8.22 | 8.94 | 2.77 | 7.79 | 7.78 | — |
| Diluted EPS | 8.16 | 8.88 | 2.76 | 7.79 | 7.78 | — |
| Revenue per Share | 47.08 | — | — | — | — | — |
| Basic Weighted Avg Shares | 174.2 | 174.1 | 173.2 | 172.7 | 172.7 | — |
| Diluted Weighted Avg Shares | 175.5 | 175.3 | 173.7 | 172.7 | 172.7 | — |
| Supplemental | ||||||
| EBITDA | — | 2,670.0 | 1,591.0 | 2,253.0 | 2,271.0 | — |
| EBIT | — | 2,181.0 | 1,036.0 | 1,692.0 | 1,693.0 | — |
| Effective Tax Rate | 15.3% | 9.2% | 21.0% | 19.3% | 20.6% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.